IgA nephropathy trials in Thailand

2 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Where

  Bangkok

  Age

  18 years to 100 years

  People

  540 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT04557462 · EU 2023-508690-92-00
• Phase 2/3Enrolling by invitation
  Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

  Where

  Bangkok, Chiang Mai, Din Daeng, Khon Kaen

  Age

  18 years and over

  People

  600 worldwide

  Run by

  Otsuka Pharmaceutical Development & Commercialization, Inc.

  See details and how to joinNCT05248659